New camera could catch ovarian cancer before it starts
NCT ID NCT02365779
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a special microscope called Cellvizio that lets doctors see inside the fallopian tubes in real time during surgery. The goal was to find early precancerous lesions that might lead to ovarian cancer. Forty women having their fallopian tubes removed for various reasons took part. Researchers compared the images from the microscope with standard lab tests to see if the new method works well.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cellvizio confocal laser endomicroscopy system
- What this could lead to
- If successful, this imaging technique could help doctors find early signs of ovarian cancer in the fallopian tubes, potentially allowing for earlier treatment and better outcomes.
- What could go wrong
- This is a small, early-stage study focused on testing the imaging method, not on treating cancer. The technique may not reliably detect all precancerous lesions, and results may not apply to broader populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
40 people
The number who actually took part.
- Start date
-
Jan 2015
- Finished
-
Aug 2015
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Woman aged 18 years or more * All patients with laparoscopic salpingectomy for benign conditions (tubal ligation, during a hysterectomy), for prophylactic conditions (BRCA mutation) or in case of pelvic cancers * Informed and signed consent Exclusion Criteria: * Interview revealing disorder entailing unacceptable risk of postoperative complications: coagulation disorder, immune system disorder, evolutive disease, etc. * Pregnancy, ongoing or planned during the study period * Allergy to fluorescein * Previous allergy or anaphylactic shock during an angiography * Allergic or hypersensibility reactions * Severe asthma, chronic cardiac or pulmonary diseases * Restricted renal function * Patient under a beta-blockers treatment * Inability to understand information provided * Not covered by a national health insurance scheme, prisoner or under administrative supervision
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bilateral laparoscopic salpingectomy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service de Gynécologie, Hôpital Femme Mère Enfant, Lyon
Bron, 69500, France